TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26493461
Drug: Education programme
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education programme focused on health-related information relevant to older adults, delivered through the tablet computer via weekly fact sheets.
Study: 18643839
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy (insulin detemir once daily and insulin aspart mealtimes)
Study: 18643839
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin aspart 30 (30% rapid-acting insulin aspart), twice daily
Study: 17848650
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of folic acid (40 mg), pyridoxine hydrochloride (100 mg), and cyanocobalamin (2 mg) daily
Study: 17848650
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of folic acid and B vitamins
Study: 9141924
Drug: Alfentanil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (40 micrograms/kg IV bolus) followed by infusion (1 microgram.kg‐1.min‐1 during surgery and 0.5 microgram.kg‐1.min‐1 postoperatively)
Study: 9141924
Drug: Sufentanil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (5 micrograms/kg IV bolus) followed by infusion (0.01 microgram.kg‐1.min‐1 during surgery and 0.005 microgram.kg‐1.min‐1 postoperatively)
Study: 9355669
Drug: Prednisone (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (more than 0.16 mg/kg/day for more than 6 months)
Study: 2852609
Drug: Fluconazole, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole, single oral 150 mg dose
Study: 2852609
Drug: Ketoconazole, 200
Normalized name: Ketoconazole, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole, 200 mg twice daily for 5 days
Study: 30445389
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP)
Study: 30445389
Drug: Waitlist/Treatment-as-Usual (WL/TAU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist/Treatment-as-Usual (WL/TAU)
Study: 23963046
Drug: Sildenafil (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (doses: 37.5 mg, 50 mg, 100 mg)
Study: 15785088
Drug: Acyclic retinoid
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclic retinoid (oral administration for 12 months)
Study: 12034658
Drug: Losartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan treatment for 12 months in patients with severe fibrosis (n=7)
Study: 7790707
Drug: Propylthiouracil (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil (300 mg)
Study: 2220013
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg pimobendan
Study: 2220013
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg pimobendan
Study: 87829
Drug: 2-month regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-month regimen of chemotherapy (daily streptomycin, isoniazid, rifampicin, and pyrazinamide)
Study: 87829
Drug: 3-month regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month regimen of chemotherapy (daily streptomycin, isoniazid, rifampicin, and pyrazinamide)
Study: 24284610
Drug: Chewable tablet
Normalized name: Chewable Tablet
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewable tablet (200 mg vitamin C)
Study: 24284610
Drug: Kiwifruit-derived vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kiwifruit-derived vitamin C (equivalent dose from gold kiwifruit)
Study: 24284610
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C tablet
Study: 15496648
Drug: Amprenavir-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir-containing combination therapy with nucleoside reverse transcriptase inhibitors
Study: 3501546
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin calcium (5-formyl-THF) at doses of 40 mg, 60 mg, 80 mg, and 100 mg
Study: 3501546
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral leucovorin calcium
Study: 3501546
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous leucovorin calcium
Study: 3501546
Drug: Oral leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral leucovorin calcium
Study: 29180640
Drug: CSII therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII therapy
Study: 29215299
Drug: MDI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI therapy
Study: 29215299
Drug: CSII therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII therapy at 12 months
Study: 29215299
Drug: CSII therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII therapy after crossover from MDI
Study: 24766974
Drug: Amiodarone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (up to 450 mg)
Study: 24766974
Drug: Lidocaine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (up to 180 mg)
Study: 12548295
Drug: 100 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/day of berries (black currants, lingonberries and bilberries) for 8 weeks
Study: 8403586
Drug: Sustained-release flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release flurbiprofen 200 mg
Study: 2906886
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg acrivastine given three times daily
Study: 2906886
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg acrivastine given three times daily
Study: 2906886
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg clemastine given three times daily
Study: 25322607
Drug: Dexmedetomidine low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine low maintain dose (0.2 microg x kg(‐1) x h(‐1))
Study: 25322607
Drug: Dexmedetomidine high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine high maintain dose (0.7 microg x kg(‐1) x h(‐1))
Study: 22566538
Drug: Zinc (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (10 mg)
Study: 20484548
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + Folic Acid (12.5 mg iron + 50 microg folic acid)
Study: 20484548
Drug: Zinc +
Normalized name: GNP Cal Mag Zinc + D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc + Iron + Folic Acid (10 mg zinc + 12.5 mg iron + 50 microg folic acid)
Study: 14572943
Drug: Video presentations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video presentations about nicotine replacement treatment (NRT)
Study: 10470219
Drug: Inhaled IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled IL-2 (high-dose)
Study: 7567847
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group, n = 25)
Study: 1770153
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of alprazolam
Study: 25848210
Drug: HX‐1171, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX‐1171, single ascending doses of 20, 40, 80, 160, 300, 600, 1,200, 1,500 or 2,000 mg administered to 67 subjects.
Study: 25848210
Drug: HX‐1171, multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX‐1171, multiple ascending doses of 500 or 1,000 mg administered to 16 subjects for 14 days.
Study: 25848210
Drug: HX‐1171, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: HX‐1171, single and multiple doses.
Study: 21084767
Drug: Ammonium chloride
Normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ammonium chloride treatment
Study: 30237219
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate treatment
Study: 21084767
Drug: Ammonium chloride
Normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ammonium chloride treatment (PEPT2*2/*2)
Study: 21084767
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate treatment (PEPT2*1/*1)
Study: 19861194
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (oral group)
Study: 17978987
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of denicotinized cigarettes (Quest 3) and 21‐mg nicotine patch for 2 weeks before the quit date
Study: 15195985
Drug: Home training
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home training (HT) - twice‐daily functional balance and strength exercises and 3 group meetings
Study: 15195985
Drug: Combined training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined training (CT) - group training twice weekly and the same home exercises
Study: 9152568
Drug: 20-mg SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg SR morphine sulfate capsule administered while fasting
Study: 9152568
Drug: 20-mg SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg SR morphine sulfate capsule administered after a high-fat meal
Study: 7525038
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg every 4 weeks
Study: 3496872
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (25 mg/kg twice daily for 14 days)
Study: 1448311
Drug: Topical chloramphenicol
Normalized name: chloramphenicol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical chloramphenicol
Study: 3496872
Drug: Severe conjunctivitis
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe conjunctivitis treatment
Study: 29945711
Drug: Progesterone 200
Normalized name: progesterone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone 200 mg vaginally daily from 22+0 to 24+0 weeks until 34+0 weeks' gestation
Study: 26441180
Drug: Laparoscopic rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic rectal resection (n=238)
Study: 26441180
Drug: Open laparotomy
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open laparotomy and rectal resection (n=237)
Study: 20951235
Drug: Exposure-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based therapy for PTSD delivered via telehealth technology
Study: 20951235
Drug: Exposure-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based therapy for PTSD delivered in-person
Study: 18468736
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 400mg, three times daily for 12 weeks
Study: 8866928
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine (50 mg in 4 ml saline)
Study: 8866928
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (10 mg solution)
Study: 9552779
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (5 mg)
Study: 6403140
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer supplementation (Caloreen) at 6 g/kg body weight daily
Study: 29506460
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (antibiotics stopped according to physicians' discretion)
Study: 25074713
Drug: Dermal scarification
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal scarification (1 ml normal saline injection)
Study: 18981503
Drug: rDEN4Delta30-200,201 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rDEN4Delta30-200,201 vaccine (10^5 PFU)
Study: 9825368
Drug: Propafenone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (600 mg single oral dose)
Study: 2664816
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (1 g amoxycillin/200 mg clavulanic acid, 3 to 4 intravenous doses per day for mean 7.7 days, followed by 500 mg amoxycillin/125 mg clavulanic acid, 4 to 6 tablets per day for mean 11.2 days)
Study: 2664816
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (3 to 4 g amoxycillin or ampicillin, 160 mg gentamicin, and 1.5 g metronidazole, parenteral therapy for mean 7.7 days, followed by 2 to 3 g amoxycillin or ampicillin and 1 to 1.5 g metronidazole daily for mean 11.1 days)
Study: 31385202
Drug: Choline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline plus magnesium (1000 mg choline bitartrate and 500 mg magnesium oxide)
Study: 31385202
Drug: Magnesium (500
Normalized name: magnesium gluconate 27 mg magnesium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (500 mg magnesium oxide)
Study: 31385202
Drug: Choline (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline (1000 mg choline bitartrate)
Study: 29904752
Drug: HEMA-free 1-step
Normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HEMA-free 1-step self-etch adhesive (1SEa G-Bond)
Study: 24214373
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg single oral dose
Study: 17976224
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (25 microg)
Study: 16620263
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (202.65 kPa for 90 min, 5 days a week for 4 weeks)
Study: 16620263
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hyperbaric therapy)
Study: 12568840
Drug: Oral 17beta‐E(2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17beta‐E(2) administration from cycle day 20 until the next cycle day 2.
Study: 12568840
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no E(2) administration).
Study: 11689712
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) certoparin, self-administered for 3 months
Study: 9130335
Drug: Ethanol (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.9 g/kg)
Study: 3147477
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zolpidem (ZOL)
Study: 3147477
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg chlorpromazine (CPZ)
Study: 3147477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ZOL + CPZ
Study: 1771605
Drug: Terbutaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (1 mg) via metered dose inhaler
Study: 1771605
Drug: Terbutaline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (2 mg total: 1 mg from each inhaler) via both inhalers
Study: 1771605
Drug: Terbutaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (1 mg) via dry powder inhaler
Study: 1771605
Drug: Terbutaline via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline via metered dose inhaler
Study: 1771605
Drug: Terbutaline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (1 mg) via both inhalers
Study: 20518813
Drug: Effervescent tablets
Normalized name: Hydralyte Effervescent Tablets Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablets
Study: 23885993
Drug: High-lignan FLX
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-lignan FLX (0.41 g lignans)
Study: 23885993
Drug: Regular FLX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular FLX (0.15 g lignans)
Study: 21157106
Drug: atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 40mg
Study: 27679519
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with losartan and lisinopril
Study: 15166558
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture (press needles at relaxation, tranquilizer point, and master cerebral point)
Study: 11450179
Drug: Bupropion, sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion, sertraline, and venlafaxine as adjuncts to mood stabilizers
Study: 7995315
Drug: Both written
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both written and oral information
Study: 30325753
Drug: Antigen-specific immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen-specific immunotherapy (cancer vaccination)
Study: 30325753
Drug: Neoadjuvant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant administration of ICI
Study: 28450350
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg/day) for 12 months
Study: 17043189
Drug: Topical calcipotriene
Normalized name: calcipotriene Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcipotriene
Study: 10934569
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (24.52 hours per week for one year, gradually reducing over 1 to 2 years)
Study: 9013398
Drug: Velnacrine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine (10, 25, 50 and 75 mg t.i.d.)
Study: 3912621
Drug: CMFVP for
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFVP for 1 year and/or hormonal therapy (ER+ patients)
Study: 29489066
Drug: OBE022 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE022 administered after a standardized breakfast on day 1 and in the fasted state from day 3 to day 9
Study: 25315893
Drug: 7.5% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% hydrogen peroxide (Oral B 3D White, Oral‐B)
Study: 18058653
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol alone (group P)
Study: 18058653
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol with oral midazolam premedication (group M + P)
Study: 11910594
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 micrograms per 24 hours)
Study: 8560293
Drug: Clinic-based smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based smoking cessation interventions, details on dosage and duration not available
Study: 6771931
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg nitroglycerin perlingual application
Study: 6771931
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg inhalatively given isoprenalin
Study: 25922424
Drug: 12-week individual
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week individual CBT plus 400 mg/day modafinil
Study: 25922424
Drug: 12-week individual
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week individual CBT plus 400 mg/day modafinil (high adherent patients)
Study: 18277886
Drug: Omeprazole maintenance
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole maintenance therapy
Study: 14515063
Drug: M201V [corrected]
Approvals — FDA: no, EMA: no, PMDA: no
Description: M201V [corrected] CysLT2 receptor variant
Study: 30506183
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of botulinum toxin
Study: 29415699
Drug: Adherence-supporting app
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence-supporting app with daily treatment reminders and electronic monitor (EM) for Cal/BD cutaneous foam.
Study: 29415699
Drug: Adherence-supporting app
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence-supporting app with daily treatment reminders and EM for Cal/BD cutaneous foam.
Study: 21878788
Drug: Short-term dynamic
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dynamic therapy
Study: 24884340
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and Short-term dynamic therapy
Study: 6437840
Drug: DHM 32-550
Normalized name: DHMS
DrugBank: Dihydrostreptomycin (DB11512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHM 32-550 (high dosage)
Study: 6437840
Drug: DHM 32-550
Normalized name: DHMS
DrugBank: Dihydrostreptomycin (DB11512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHM 32-550 (low dosage)
Study: 30929188
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm
Study: 25377067
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment to suppress all electrographic seizure activity
Study: 25377067
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment of electroencephalographic status epilepticus